Purchase Order 75N91019P00572

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,480.00 on May 22, 2020, with completion scheduled for June 29, 2021. Work is performed in San Diego, California. The order is firm fixed price with no set-aside designation. Acea Biosciences is a subsidiary of Agilent Technologies and supplies life sciences instrumentation, software, consumables, and services to federal research organizations.</p>

The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $22,504.00 on March 1, 2018, with a completion date of August 31, 2018. The order is a firm fixed price, commercial acquisition with no small business set-aside. Performance takes place in Bethesda, Maryland. The procurement covers specialized life sciences equipment, instrumentation, or related services aligned with Acea's portfolio of flow cytometry, cell analysis, and biosensing products for research...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $2,916.59 on July 1, 2014, for preventative maintenance service on an Xcelligence DP invasion machine (Serial # 32-1110-1728-7). Performance is in Bethesda, Maryland, with completion by June 30, 2015. The order was placed under firm fixed-price terms with no small business set-aside.</p>

<p>The National Cancer Institute issued a purchase order to Acea Biosciences, Inc. on June 27, 2019 for maintenance agreement services with a ceiling value of $15,627.60 and an ultimate completion date of June 29, 2020. Place of performance is San Diego, California. The order was awarded under firm fixed price on a no-set-aside basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,627.60 on June 29, 2017, with completion by June 30, 2018. No set-aside applies. Work is performed in San Diego, California. The order covers life sciences instrumentation, software, services, consumables, and expertise related to flow cytometry and cell analysis technology, priced on a firm fixed price basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for extended warranty services valued at $3,004.32 on February 20, 2020, with an ultimate completion date of February 28, 2021. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation. This purchase order was issued to de-obligate fiscal year 2020 expiring lines per NIH OALM communication 25-06.</p>

This contract was awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Acea Biosciences, Inc. for the acquisition of an xCELLigence RTCA-MP equipment package. The contract is a firm fixed-price purchase order with a potential value of $134,995.95. There was no set-aside designation for this award. Acea Biosciences is a life sciences company that provides specialized equipment, software, services, and expertise related to flow...

The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. for one xCELLigence cell analyzer system valued at $151,446.20 on June 19, 2026, under sole-source authority (FAR 6.302-1). The equipment will be placed at Marshton, Delaware and will support the CCR Genomics Core's development of novel cell-based cancer therapies, including CAR and TCR-based therapies, antibody-drug conjugates, and small-molecule agents. The xCELLigence RTCA MP system provides non-invasive,...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. valued at $4,275.00 on February 5, 2020, for a service agreement to de-obligate expiring FY20 lines. Work is performed at Bethesda, Maryland. The order carries firm fixed pricing and completed on February 28, 2021. No set-aside applied.</p>

<p>The National Institutes of Health awarded a purchase order to Acea Biosciences, Inc. for $135,000 on June 12, 2017, to procure an xCELLigence RTCA-MP bundle. Performance takes place in Bethesda, Maryland, with completion scheduled for June 23, 2017. The order carries firm fixed pricing and no set-aside designation.</p>